

Title (en)

CANCER ASSOCIATED ANTIGENS AND USES THEREFOR

Title (de)

MIT KREBS IN VERBINDUNG STEHENDE ANTIGENE UND DEREN VERWENDUNG

Title (fr)

ANTIGENES ASSOCIES AU CANCER ET UTILISATIONS CORRESPONDANTES

Publication

**EP 1208380 A2 20020529 (EN)**

Application

**EP 00936286 A 20000524**

Priority

- US 0014391 W 20000524
- US 32009299 A 19990526

Abstract (en)

[origin: WO0072021A2] Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast cancer and/or T cell leukemia cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention provides, *inter alia*, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

IPC 1-7

**G01N 33/574**; **C12Q 1/68**; **A61K 39/00**; **A61K 48/00**; **A61K 39/395**; **C12N 15/63**; **C12N 5/10**; **C07K 14/47**; **C07K 7/04**; **A61K 35/14**; **C07K 16/18**

IPC 8 full level

**G01N 33/53** (2006.01); **A61K 31/7088** (2006.01); **A61K 35/76** (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61K 39/39** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 14/47** (2006.01); **C07K 14/82** (2006.01); **C07K 16/32** (2006.01); **C12N 1/15** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12P 21/08** (2006.01); **C12Q 1/68** (2006.01); **C12Q 1/6886** (2018.01); **G01N 33/574** (2006.01)

CPC (source: EP US)

**A61K 39/0011** (2013.01 - US); **A61K 39/4611** (2023.05 - EP); **A61K 39/464499** (2023.05 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 14/4748** (2013.01 - EP); **C12Q 1/6886** (2013.01 - EP); **G01N 33/574** (2013.01 - EP); **A61K 38/00** (2013.01 - EP); **A61K 2039/53** (2013.01 - EP); **C12Q 2600/158** (2013.01 - EP)

Citation (search report)

See references of WO 0072021A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**WO 0072021 A2 20001130**; **WO 0072021 A3 20020404**; AU 5162400 A 20001212; EP 1208380 A2 20020529; JP 2003500072 A 20030107

DOCDB simple family (application)

**US 0014391 W 20000524**; AU 5162400 A 20000524; EP 00936286 A 20000524; JP 2000620358 A 20000524